Ondansetron is a potent, selective and competitive antagonist at serotonin (5-HT 3 ) receptors 1 . Identical receptors, located presynaptically on primary sensory fibres in the dorsal horn of the spinal cord, are involved in pain modulation 2,3 . Pretreatment with ondansetron and granisetron enhances regression of sensory block after intrathecal administration of 5% hyperbaric lignocaine 4 and hyperbaric bupivacaine 5 respectively. In contrast, pretreatment with high dose ondansetron has no effect on the duration of motor and sensory block after subarachnoid anaesthesia with ropivacaine 6 .
Ondansetron is a potent, selective and competitive antagonist at serotonin (5-HT 3 ) receptors 1 . Identical receptors, located presynaptically on primary sensory fibres in the dorsal horn of the spinal cord, are involved in pain modulation 2, 3 . Pretreatment with ondansetron and granisetron enhances regression of sensory block after intrathecal administration of 5% hyperbaric lignocaine 4 and hyperbaric bupivacaine 5 respectively. In contrast, pretreatment with high dose ondansetron has no effect on the duration of motor and sensory block after subarachnoid anaesthesia with ropivacaine 6 .
Antiemetics such as ondansetron are often administered in the perioperative period 7 , so a possible interaction with local anaesthetic agents, including the effect on intensity and duration of spinal block, needs to be clarified. We conducted this study with the objective of assessing whether intravenous ondansetron affected the duration of sensory and motor block. Secondary outcomes were the time to peak sensory block and regression of sensory and motor block.
METHODS
This was a randomised, double-blind clinical trial in which 60 patients undergoing transurethral resection of bladder tumours under spinal anaesthesia were included (30 per group). The study was approved by the hospital ethics committee and written informed consent obtained from all patients. Randomisation was done by means of a random number chart. Patients were allocated into groups by means of sealed envelopes containing the randomly determined treatment assignment. Envelopes were labelled with a subject number and opened in numerical order in the operating theatre. Patients in group 1 (ondansteron) received 4 mg (2 ml) of ondansetron whereas patients in group 2 (control) received placebo (2 ml of normal saline) 15 minutes prior to subarachnoid block with 2.5 ml of 0.5% hyperbaric bupivacaine. Two investigators were involved in the study conduct. The drug solutions were made by one investigator, who did not have subsequent involvement in data collection. All assessments in the study were performed by the second investigator who was blinded to the contents of the study syringe.
Exclusion criteria were patients with a history of back surgery, uncontrolled hypertension, a nervous system disorder, intake of analgesics (e.g. paracetamol, nonsteroidal anti-inflammatory drugs with or without opioids), alpha 2 -agonists, calcium channel blockers, patients with known hypersensitivity to SUMMARY Ondansetron is a potent antiemetic and a competitive antagonist at serotonin receptors, which are also involved in modulation of pain. This study was designed to assess the effect of systemic ondansetron on sensory and motor block after subarachnoid anaesthesia with hyperbaric bupivacaine. Sixty patients undergoing transurethral resection of bladder tumours were randomly assigned to one of two groups. Group 1 received 2 ml (4 mg) of ondansetron whereas patients in group 2 received 2 ml of normal saline 15 minutes prior to administration of subarachnoid block with 2.5 ml of hyperbaric bupivacaine 0.5%. Time to attain peak sensory block (P=0.27), time to two segment regression (P=0.19) and time to regression to the S 2 dermatome (P=0.84) did not significantly differ between the two groups. No differences in regression of sensory block were noted at any time. The mean duration of motor block also did not differ (P=0.44), with similar regression of block at all time intervals except at 90 minutes.
We concluded that intravenous ondansetron does not affect the intensity or duration of sensory and motor block after spinal anaesthesia with hyperbaric bupivacaine.
local anaesthetic or with another contraindication to spinal anaesthesia. All patients were fasted for eight hours for solid food and no premedication was given.
In the operating theatre an intravenous infusion was maintained with sodium chloride 0.9% at 8 ml/kg/hour. Electrocardiogram, non-invasive blood pressure and a pulse oximeter were attached. Lumbar puncture was performed with the patient in the lateral decubitus position using a 26 gauge Quincke needle at the L2-L3 or L3-L4 intervertebral space in the midline. The time at which the intrathecal injection was made was considered to be time zero. Patients were placed in the lithotomy position once the sensory block had reached its highest level.
Sensory block was determined using a 22 gauge blunted needle in the midline, and dermatome levels were tested every two minutes after intrathecal injection until the level stabilised for four consecutive intervals. The highest dermatomal level of sensory block and the time to reach this level were noted. Motor block was assessed at the time of peak sensory level using a modified Bromage scale 8 (MBS) scored as 0=no block, 1=able to bend knee, 2=able to dorsiflex the foot and 3=complete motor block. Subsequently the level of sensory and motor block was assessed every 10 minutes throughout the intraoperative and postoperative period and time to two segment regression was noted. Heart rate and non-invasive blood pressure were noted every three minutes in the first 15 minutes after spinal anaesthesia and then every five minutes until the end of surgery. Patients requiring additional analgesics or general anaesthesia for completion of surgery were excluded from the study.
The duration of motor block was considered the time taken for MBS to return to zero and the duration of sensory block was considered the time until the block had regressed to the S2 dermatome. Adverse effects such as shivering, nausea, vomiting, headache and abdominal discomfort were noted.
Sample size estimation was done to detect a difference of 25% in the duration of block between the two groups, with power of 0.8 and alpha error of 0.05, based on hospital data revealing that the duration of block with intrathecal bupivacaine was 150 to 180 minutes with standard deviation 20 to 25% of this mean duration. P <0.05 was considered statistically significant. Student's t-test was used to analyse demographic and haemodynamic data. Inter-group differences in the levels of sensory block and the degree of motor block were tested with the Mann-Whitney U test. The incidence of adverse effects was compared with chi-square tests.
RESULTS
There were no patients excluded from the study. Groups were comparable with respect to demographic data (Table 1) . Mean (SD) surgical duration was 58.2±19.6 minutes in group 1 and 65.7±8.6 minutes in group 2 (P=not significant [NS]).
The mean (SD) duration of sensory block was 171.7 ±12.6 minutes in group 1 and 172.3±13.6 minutes in group 2 (P=NS). The mean (SD) duration of motor block was 132±13.5 minutes and 133.3±13.5 minutes in groups 1 and 2 respectively (P=NS).
The time to peak sensory block was 12.1± 1.3 minutes in group 1 and 12.5±1.6 minutes in group 2 (P=NS). The median peak cephalad spread of sensory block was T6 in both groups (range T4 to T8). Time to two segment regression was 66.0± 9.7 minutes in group 1 and 62.7±10.1 in group 2 (P=NS). Level of sensory block expressed as dermatomes (median and range), in groups 1 and 2 after 10 minutes, is shown in Table 2 . No significant difference was found between the groups in regression of sensory block up to a maximum Values are median (range). No significant differences between groups 1 (ondansetron) and 2 (control).
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Anaesthesia and Intensive Care, Vol. 39, No. 1, January 2011 assessment time of 200 minutes after intrathecal injection (Figure 1 ). The intensity of motor block, expressed as a MBS, is depicted in Figure 2 . The MBS at the time of peak sensory block was the same in both the groups (median 3, range 2 to 3) and was clinically satisfactory. A significant difference between groups in regression of motor block was found only at one time interval, at 90 minutes.
No adverse effect related to either intrathecal drug or intravenous ondansetron was reported. The intraoperative and postoperative haemodynamic parameters did not significantly differ between the groups. Six patients in group 1 and seven in group 2 experienced shivering (P=NS).
DISCUSSION
In this study intravenous ondansetron, given before subarachnoid injection of bupivacaine, had no effect on the duration of either sensory or motor block, nor on the time to peak sensory block, the intensity of sensory or motor block or the regression of sensory and motor block.
Our results agree with those of Paraskeva et al 6 who found that pretreatment with ondansetron the night before surgery and prior to spinal anaesthesia with ropivacaine had no effect on sensory block. Ropivacaine is a similar local anaesthetic to bupivacaine but less potent 9 . In contrast, Fassoulaki et al 4 demonstrated that systemic ondansetron enhanced regression of sensory block after spinal lignocaine. In their study the sensory block was assessed for 30 minutes only and the maximal dermatomal spread and total duration of block were not recorded. Due to its short duration of action and high incidence of transient neurological symptoms 10 , hyperbaric lignocaine is no longer recommended for subarachnoid block.
Mowafi et al 5 demonstrated faster recovery of sensory block after intravenous granisetron, given prior to subarachnoid block with hyperbaric bupivacaine. Granisetron is a more potent and selective 5-HT 3 receptor antagonist 11 than ondansetron. It is metabolised primarily by cytochrome P-450(CYP)3A isozyme 12 whereas ondansetron is metabolised via a number of CYP450 enzymes 13 . Variability in the pharmacokinetics of granisetron in comparison to ondansetron is explained by the heterogeneity in CYP3A activity. Ondansetron is non-selective and acts on a range of receptor subtypes (5-HT 1A-D , 5-HT 2A-C , 5-HT 3 , 5-HT 4 ), all of which are expressed in central and peripheral neurones 14 . Serotonin exerts both an inhibitory and excitatory influence on pain processing via these receptors 15, 16 . These factors may account for the difference in results between our study using ondansetron and the study using granisetron. Our research methodology differed from the previous studies in that data on regression of motor and sensory block were collected more frequently. It also differed in that pretreatment with the 5-HT 3 antagonist occurred only once prior to spinal anaesthesia, omitting an additional dose the night before surgery. In addition, we gave 4 mg whereas Paraskeva et al 6 administered 8 mg of ondansetron.
One potential limitation of our study was in the method used to test sensory block. Assessment of loss and return of the pinprick sensation was performed using a 22 gauge blunt needle but pinprick intensity varies with each measurement and stimulus variability may cause variability in response. Also, significant variability is present in the evaluation of sensory block, even for the same stimulus intensity in different patients. Measurements in the intraoperative period were done with the patient in the lithotomy position whereas postoperative assessments were with the patient supine, which might have affected regression of sensory block.
In conclusion, intravenous ondansetron does not affect the onset, intensity, regression or duration of spinal block produced by hyperbaric bupivacaine and can be used for prophylaxis and treatment of nausea and vomiting during regional anaesthesia without an effect on block characteristics.
